The coronavirus disease 2019 (COVID-19) pandemic requires rapid medical responses The risk of venous and arterial thromboembolism increases in critically ill patients with SARS-CoV-2 infection There is a hypercoagulable state that includes elevated levels of D-dimer, with an increased risk of organ failure and increased mortality The abnormalities described in hemostasis should be considered for therapeutic decision making We analyzed the available scientific evidence for the therapeutic approach of coagulopathy in the course of the disease with the objective of designing realistic therapeutic recommendations aimed at reducing morbidity and mortality in patients with COVID-19
Coagulopathy and COVID-19. recommendations for a changing reality